Rapid Commercialization of Fruquintinib in the Treatment of Metastatic Colorectal Cancer: A New Benchmark for Chinese Innovative Drugs Going Global

On November 9th, the U.S. Food and Drug Administration (FDA) approved the use of fruquintinib, developed by Hengrui Medicine and Takeda, for the treatment of refractory metastatic colorectal cancer (mCRC). Within 48 hours of receiving approval, fruquintinib had already been prescribed, signaling a remarkable feat in commercialization. This swift commercialization not only reflects the efforts made by Takeda in the early stages of commercial development but also reveals the significant unmet needs among mCRC patients. Multiple factors have contributed to the rapid uptake of fruquintinib in the United States, laying a solid foundation for its success.

The Global Burden of Colorectal Cancer:
Colorectal cancer (CRC), which includes colon and rectal cancer, ranks as the third most common cancer and the second leading cause of cancer-related deaths worldwide. The majority of metastatic CRC patients cannot be cured, with approximately 20% of CRC patients presenting with metastasis at diagnosis and over 50% experiencing metastasis during the course of their disease. In the United States, it is estimated that there will be 153,000 new cases of colorectal cancer in 2023, accounting for 7.8% of all new cancer cases and ranking as the second leading cause of cancer-related deaths. Around 70% of colorectal cancer patients have metastasis either at diagnosis or after treatment, making metastasis the primary cause of colorectal cancer-related deaths.

The Urgent Need for Effective Treatments:
Metastatic colorectal cancer lacks effective treatment options, and patients often have poor prognoses. The survival rates for colorectal cancer vary depending on the stage at diagnosis, with a 5-year survival rate of 94% for stage I, 82% for stage II, 67% for stage III, and only 11% for metastatic or stage IV colorectal cancer.

The Promise of Fruquintinib:
Fruquintinib, as a next-generation VEGFR inhibitor, has demonstrated significant improvements in overall survival and progression-free survival for mCRC patients in global clinical trials. It not only addresses the toxicities associated with first-generation products but also offers substantial survival benefits without negatively impacting patients' quality of life. The expedited uptake of fruquintinib in the United States is indicative of its potential to provide significant clinical benefits for patients with refractory metastatic colorectal cancer.

The Success of Fruquintinib and Future Prospects:
The rapid overseas sales of fruquintinib find precedent in the success of regorafenib, a recommended third-line therapy for colorectal cancer in major guidelines. Hengrui Medicine's Syk inhibitor, soplodipine, holds promise as their next pipeline candidate for international expansion. With the successful completion of Phase III clinical trials for the treatment of adult primary immune thrombocytopenia (ITP), soplodipine is expected to become the second globally approved Syk inhibitor upon its anticipated NDA submission in 2023.

Syk, a non-receptor tyrosine kinase (RTK), plays a vital role in immune cells, particularly in B cells and mast cells, mediating signaling pathways of immune receptors and other cell receptor-mediated immune responses. Targeting Syk with inhibitors can suppress the activity of immune cells, thereby interfering with the occurrence and progression of inflammation and immune-related diseases.

While ITP may not represent a large indication, soplodipine's excellent safety profile positions it to excel in this indication, overcoming the limitations of high rates of severe side effects such as diarrhea and hypertension associated with Fostamatinib, the first approved Syk inhibitor. Additionally, soplodipine's potential extends beyond ITP, as preliminary clinical trials for NHL in the United States and Europe, as well as Phase II/III trials for hemolytic anemia, are already underway.

The rapid commercialization of fruquintinib in the United States for the treatment of metastatic colorectal cancer exemplifies the significant unmet needs in this patient population. The success of fruquintinib underscores the potential for Chinese innovative drugs to make a global impact. Furthermore, Hengrui Medicine's soplodipine, a Syk inhibitor, holds promise as the company's next candidate for international expansion. The development of Syk inhibitors not only for autoimmune diseases but also for inflammatory diseases, lymphomas, and solid tumors, opens up additional avenues for the release of soplodipine's value through external business development activities.